CD163 and metabolic dysfunction-associated steatotic liver disease: Substantial evidence has demonstrated a positive relationship between circulating soluble cluster of differentiation 163 (sCD163) concentrations and obesity-related comorbidities such as diabetes, non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome (MetS) [1,2].